References
1. National ENTTRN. The British Rhinological Society multidisciplinary
consensus recommendations on the hospital management of epistaxis. J
Laryngol Otol 2017; 131:1142-1156.
2. Escabasse V, Bequignon E, Verillaud Bet al. Guidelines of the French
Society of Otorhinolaryngology (SFORL). Managing epistaxis under
coagulation disorder due to antithrombotic therapy. Eur Ann
Otorhinolaryngol Head Neck Dis 2017; 134:195-199.
3. Garneau JC, Wasserman I, Konuthula N, Malkin BD. Referral patterns
from emergency department to otolaryngology clinic. Laryngoscope 2018;
128:1062-1067.
4. Tunkel DE, Anne S, Payne SCet al. Clinical Practice Guideline:
Nosebleed (Epistaxis). Otolaryngol Head Neck Surg 2020; 162:S1-S38.
5. Nikolaou G, Holzmann D, Soyka MB. Discomfort and costs in epistaxis
treatment. Eur Arch Otorhinolaryngol 2013; 270:2239-2244.
6. Althaus AE, Luske J, Arendt Uet al. Treating epistaxis - who cares
for a bleeding nose? A secondary data analysis of primary and secondary
care. BMC Fam Pract 2021; 22:75.
7. Runggaldier D, Schindler V, Luo Y, Kleinjung T, Soyka MB. Novel oral
anticoagulation treatment is not associated with recurrent or severe
epistaxis. Rhinology 2021; 59:219-221.
8. Yaniv D, Zavdy O, Sapir E, Levi L, Soudry E. The Impact of
Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on
Epistaxis. Laryngoscope 2021.
9. Kallenbach M, Dittberner A, Boeger Det al. Hospitalization for
epistaxis: a population-based healthcare research study in Thuringia,
Germany. Eur Arch Otorhinolaryngol 2020; 277:1659-1666.
10. Althaus AE, Arendt U, Hoffmann Fet al. [Epistaxis and
anticoagulation therapy: an analysis based on health insurance data from
Lower Saxony]. HNO 2021; 69:206-212.
11. Hindricks G, Potpara T, Dagres Net al. 2020 ESC Guidelines for the
diagnosis and management of atrial fibrillation developed in
collaboration with the European Association for Cardio-Thoracic Surgery
(EACTS). Eur Heart J 2021; 42:373-498.
12. Ortel TL, Neumann I, Ageno Wet al. American Society of Hematology
2020 guidelines for management of venous thromboembolism: treatment of
deep vein thrombosis and pulmonary embolism. Blood Adv 2020;
4:4693-4738.
13. Stankovic P, Georgiew R, Frommelt Cet al. Shorter hospital stays in
epistaxis patients with atrial fibrillation when taking rivaroxaban or
apixaban versus phenprocoumon. J Thromb Thrombolysis 2019; 47:384-391.
14. Page MJ, McKenzie JE, Bossuyt PMet al. The PRISMA 2020 statement: an
updated guideline for reporting systematic reviews. BMJ 2021; 372:n71.
15. FDA Approval Dabigatran. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512orig1s000toc.cfm.
Accessed 26.04.2021.
16. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J.
Methodological index for non-randomized studies (minors): development
and validation of a new instrument. ANZ J Surg 2003; 73:712-716.
17. L’Huillier V, Badet C, Tavernier L. Epistaxis complicating treatment
by anti-vitamin K and new oral anticoagulants. Eur Ann Otorhinolaryngol
Head Neck Dis 2018; 135:231-235.
18. Gokdogan O, Akyildiz I, Sayin BY, Okutucu S, Tanalp AC, Arslan N.
The Rate of Epistaxis Incidence in New-Generation Anticoagulants and
Perioperative Approach in Otorhinolaryngological Practices. J Craniofac
Surg 2017; 28:e178-e182.
19. García Callejo FJ, Bécares Martínez C, Calvo González J, Martínez
Beneyto P, Marco Sanz M, Marco Algarra J. Epistaxis and dabigatran, a
new non-vitamin K antagonist oral anticoagulant. Acta Otorrinolaringol
Esp 2014; 65:346–354.
20. Send T, Bertlich M, Horlbeck Fet al. Management and outcome of
epistaxis under direct oral anticoagulants: a comparison with warfarin.
Int Forum Allergy Rhinol 2019; 9:120-124.
21. Buchberger AMS, Baumann A, Johnson Fet al. The role of oral
anticoagulants in epistaxis. Eur Arch Otorhinolaryngol 2018;
275:2035-2043.
22. Glikson E, Chavkin U, Madgar Oet al. Epistaxis in the setting of
antithrombotic therapy: A comparison between factor Xa inhibitors,
warfarin, and antiplatelet agents. Laryngoscope 2019; 129:119-123.
23. Sauter TC, Hegazy K, Hautz WEet al. Epistaxis in anticoagulated
patients: Fewer hospital admissions and shorter hospital stays on
rivaroxaban compared to phenprocoumon. Clin Otolaryngol 2018;
43:103-108.
24. Davies T, Alatsatianos A, Slim MAM, Royce W, Whymark A. The impact
of frailty on epistaxis admission, a retrospective cohort study. Clin
Otolaryngol 2021.
25. Sethi RKV, Kozin ED, Abt NB, Bergmark R, Gray ST. Treatment
disparities in the management of epistaxis in United States emergency
departments. Laryngoscope 2018; 128:356-362.
26. Cooper SE, Ramakrishnan VR. Direct cauterization of the nasal septal
artery for epistaxis. Laryngoscope 2012; 122:738-740.
27. Fleck R.A., Rao M., Rapaport S., N. V. Localization of human tissue
factor antigen by immunostaining with monospecific, polyclonal
anti-human tissue factor antibody. Thrombosis Research 1990; 59:421-437.
28. Thornton MA, Mahesh BN, Lang J. Posterior epistaxis: identification
of common bleeding sites. Laryngoscope 2005; 115:588-590.
29. Kawabori M, Niiya Y, Iwasaki Met al. Characteristics of Symptomatic
Intracerebral Hemorrhage in Patient Receiving Direct Oral
Anticoagulants: Comparison with Warfarin. Journal of Stroke and
Cerebrovascular Diseases 2018; 27:1338-1342.
30. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range INR
values and outcomes among new warfarin patients with non-valvular atrial
fibrillation. Int J Clin Pharm 2015; 37:53-59.
31. Merli GJ, Tzanis G. Warfarin: what are the clinical implications of
an out-of-range-therapeutic international normalized ratio? J Thromb
Thrombolysis 2009; 27:293-299.
32. Neshewat J, Wasserman A, Alexandris-Souphis Cet al. Reduction in
epistaxis and emergency department visits in patients taking warfarin
after implementation of an education program. Thromb Res 2021;
199:119-122.
33. Jame S, Barnes G. Stroke and thromboembolism prevention in atrial
fibrillation. Heart 2020; 106:10-17.